To examine the tumor suppression ability of tamoxifen on ER-positive breast cancer, we first assessed the dose-dependent antiproliferative effect of tamoxifen on ER-positive human MCF7 cells (Figure 4A). The gene discussed is ESR1; the disease is neoplasm.